Siemens Healthineers to spin off in‑vitro diagnostics unit as Olyrian Diagnostics, rebranding to Healthineers

Siemens Healthineers announced it will separate its in‑vitro diagnostics division into a new standalone company called Olyrian Diagnostics.

The carve‑out will run in parallel with a corporate name change to Healthineers, and the split is targeted for completion by 2028, with the Olyrian brand introduced gradually.

The move follows a weaker‑than‑expected FY2027 outlook, where diagnostics revenue was projected to be flat and margins fell to 5.4%, prompting analysts to view the separation as a sensible step.

The diagnostics segment has faced challenges in China due to regulatory reforms and strong local competition, contributing to its status as the company's weakest business line.